Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor

Head and Neck Cancer Clinical Trial

Official title:

A Phase II Study of Cisplatin and Gemcitabine in Patients With Locally Advanced/Recurrent or Metastatic Malignant Salivary Gland Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00079079
• Other study ID #: HN4
• Secondary ID: CAN-NCIC-HN4LILL
• Status: Completed
• Phase: Phase 2
• Start date: October 27, 2003
• Est. completion date: February 10, 2009

Study information

• Verified date: April 2020
• Source: Canadian Cancer Trials Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as cisplatin, carboplatin, and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with either cisplatin or carboplatin works in treating patients with locally advanced, recurrent, or metastatic malignant salivary gland tumor (cancer).

Description:

OBJECTIVES: Primary - Determine the activity of cisplatin or carboplatin in combination with gemcitabine, in terms of response rate, in patients with locally advanced, recurrent, or metastatic malignant salivary gland tumor. Secondary - Determine the complete response in patients treated with these regimens. - Determine the duration of response in patients treated with these regimens. - Determine the toxicity profile of these regimens in these patients. - Determine the overall survival of patients treated with these regimens. OUTLINE: This is a multicenter study. Patients receive gemcitabine IV over 30 minutes on days 1 and 8. Patients also receive either cisplatin IV over 1 hour on day 2 OR carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed at 4 weeks, every 3 months for 1 year, and then every 6 months thereafter until relapse. PROJECTED ACCRUAL: A total of 11- 34 patients will be accrued for this study within 1.5-3 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: February 10, 2009
• Est. primary completion date: September 29, 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed malignant salivary gland tumor
• All histological subtypes eligible
• Locally advanced, recurrent, or metastatic disease
• Considered incurable by radiotherapy or surgery
• Low- to intermediate-grade mucoepidermoid tumor or acinic cell carcinoma allowed provided patients are symptomatic OR at imminent risk of developing symptoms attributable to metastatic disease
• Disease must meet 1 of the following criteria:
• Metastatic disease that is chemonaïve
• Metastatic disease that has progressed after a prior non-cisplatin/carboplatin/gemcitabine regimen
• Local and/or distant recurrence after curative surgery and/or radiotherapy
• Locally advanced disease not suitable for surgery or radiotherapy
• At least 1 site of unidimensionally measurable disease documented by 1 of the

following:

• At least 20 mm by X-ray, physical exam, or non-spiral CT scan
• At least 10 mm by spiral CT scan
• No bone metastases as only site of measurable disease
• No known brain metastasis PATIENT CHARACTERISTICS: Age
• 18 and over Performance status
• ECOG 0-2 Life expectancy
• At least 12 weeks Hematopoietic
• Absolute granulocyte count = 1,500/mm^3
• Platelet count = 100,000/mm^3 Hepatic
• AST/ALT no greater than 3 times upper limit of normal Renal
• Creatinine clearance at least 60 mL/min (for cisplatin) OR 30-59 mL/min (for carboplatin) Cardiovascular
• No symptomatic congestive heart failure
• No unstable angina
• No cardiac arrhythmia Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No other serious illness or medical condition that would preclude study participation
• No active uncontrolled infection
• No neurologic disorder or psychiatric illness that would preclude study compliance
• No other malignancy within the past 5 years except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy
• Not specified Chemotherapy
• See Disease Characteristics
• At least 4 weeks since prior chemotherapy for locally advanced, recurrent, or metastatic disease and recovered
• Must have been a non-cisplatin/carboplatin/gemcitabine-containing regimen
• More than 12 months since prior adjuvant chemotherapy (including cisplatin/carboplatin-based regimens) and recovered
• No prior gemcitabine Endocrine therapy
• Not specified Radiotherapy
• See Disease Characteristics
• At least 4 weeks since prior radiotherapy and recovered
• No prior radiotherapy to only site of measurable disease unless there is documented disease progression after therapy Surgery
• See Disease Characteristics
• At least 21 days since prior surgery and recovered Other
• More than 30 days since prior anticancer therapy
• More than 30 days since prior investigational agents
• No other concurrent anticancer therapy
• No other concurrent investigational agents

Related Conditions & MeSH terms

• Head and Neck Cancer
• Salivary Gland Neoplasms

Intervention

Drug:
• carboplatin

• cisplatin

• gemcitabine hydrochloride

Locations

Country	Name	City	State
Canada	London Regional Cancer Program at London Health Sciences Centre	London	Ontario
Canada	Ottawa Hospital Regional Cancer Centre - General Campus	Ottawa	Ontario
Canada	Princess Margaret Hospital	Toronto	Ontario
Canada	CancerCare Manitoba	Winnipeg	Manitoba

Sponsors (1)

Lead Sponsor	Collaborator
NCIC Clinical Trials Group

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Laurie SA, Siu LL, Winquist E, Maksymiuk A, Harnett EL, Walsh W, Tu D, Parulekar WR. A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group. Cancer. 2010 Jan 15;116(2):362-8. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response measured by RECIST criteria after accrual of 11 evaluable patients
Secondary	Toxicity assessed by NCI CTC v2.0
Secondary	Overall survival